Recovering from orthopedic surgery is often just the beginning of a patient’s journey. Even after a successful procedure, scar tissue can form around healing tendons and ligaments, limiting movement and extending rehabilitation. TYBR Health is working to address this challenge with technology designed to protect healing tissues, and the company has now secured fresh funding to accelerate that mission.
Houston-based TYBR Health has raised $30 million in Series A financing to expand access to its FDA-cleared B3 GEL® System. The funding will help the company strengthen its commercial presence, support clinical research, and broaden the potential applications of its technology for orthopedic surgery.
New Investment to Support Growth
The Series A financing was co-led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors.
According to the company, the new capital will be used to expand commercial access to the B3 GEL® System across the United States, broaden product indications, and support clinical studies that evaluate tissue protection during orthopedic procedures. The investment reflects growing confidence in TYBR Health‘s approach to improving recovery after orthopedic surgery by addressing one of the most common causes of reduced mobility post-surgical scar tissue formation.
A Technology Designed to Protect Healing Tissue
TYBR Health develops medical technologies that help surgeons protect healing soft tissues during recovery. Its flagship product, the B3 GEL® System, is a bioresorbable gel barrier applied during surgery to create temporary separation between healing tissues and surrounding structures.
The system is designed to help protect tendons, ligaments, muscles, and surrounding soft tissues during the body’s natural healing process. By reducing unwanted tissue attachment, the technology aims to preserve normal tissue movement while supporting recovery.
The product integrates into existing surgical procedures without requiring significant changes to a surgeon’s workflow, making it suitable for a wide range of orthopedic applications.
FDA-Cleared Platform Ready for Commercial Expansion
The funding follows an important milestone for TYBR Health. In June 2025, the U.S. Food and Drug Administration granted 510(k) clearance for the company’s B3 GEL® System.
The clearance allows the system to be used for protecting tendons, ligaments, skeletal muscles, and surrounding soft tissues during orthopedic procedures. This regulatory approval provided the foundation for the company’s commercial rollout, and the new investment is expected to accelerate adoption across healthcare providers. With FDA clearance already in place, TYBR Health is now focused on making the technology more widely available while continuing to generate additional clinical evidence.
Leadership Focused on Improving Patient Recovery
TYBR Health is led by Dr. Tim Keane, the company’s co-founder and Chief Executive Officer.
Commenting on the financing, Dr. Keane said the investment represents an important step toward expanding patient access to the company’s technology. He noted that the support from investors will help TYBR Health increase commercial availability of the B3 GEL® System, expand future product indications, and continue clinical research that advances soft tissue protection during orthopedic surgery.
The company believes better protection of healing tissues can contribute to improved recovery and help surgeons address challenges associated with post-operative scar formation.
Looking Ahead
Orthopedic procedures involving tendons and ligaments are performed in large numbers each year, and recovery remains a major concern for both patients and surgeons. Technologies that help protect healing tissues while fitting naturally into existing surgical practices have the potential to improve post-operative care.
With $30 million in new funding, an FDA-cleared product already on the market, and plans to expand commercial adoption and clinical research, TYBR Health is entering its next stage of growth. The latest investment positions the company to bring the B3 GEL® System to more healthcare providers while continuing to develop solutions that support better recovery following orthopedic surgery.
